In a large, national cohort trial, the use of SGLT2 inhibitors was linked with decreased risks of total respiratory events, pneumonia, and respiratory failure among T2DM patients compared to the use of DPP-4 inhibitors [47]. Here, DPP4 is linked to susceptibility to pneumonia measurement.